Regeneron Pharmaceuticals
REGN
#128
Rank
$119.62 B
Marketcap
$1,086
Share price
-0.86%
Change (1 day)
50.44%
Change (1 year)

P/E ratio for Regeneron Pharmaceuticals (REGN)

P/E ratio as of July 2024 (TTM): 29.1

According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 29.0584. At the end of 2022 the company had a P/E ratio of 17.8.

P/E ratio history for Regeneron Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202217.8115.55%
20218.26-43.98%
202014.7-23.92%
201919.417.5%
201816.5-50.5%
201733.3-22.28%
201642.9-51.34%
201588.1-23.31%
201411580.78%
201363.6192.43%
201221.7-195.69%
2011-22.7-12.12%
2010-25.9-9.13%
2009-28.456.49%
2008-18.220.44%
2007-15.133.11%
2006-11.321.23%
2005-9.35-177.18%
200412.1-276.3%
2003-6.875.09%
2002-6.54-57.96%
2001-15.6

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
23.7-18.36%๐Ÿ‡บ๐Ÿ‡ธ USA
-58.4-300.97%๐Ÿ‡บ๐Ÿ‡ธ USA
12.4-57.43%๐Ÿ‡บ๐Ÿ‡ธ USA
11.1-61.74%๐Ÿ‡บ๐Ÿ‡ธ USA
29.9 2.87%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
15.8-45.67%๐Ÿ‡ซ๐Ÿ‡ท France

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.